支气管舒张试验在哮喘患者诊断中的应用

Application of bronchodilator reversibility tests in diagnosis of asthma

目的研究各项通气功能指标在哮喘患者支气管舒张试验中的变化和诊断价值。方法测定30例哮喘患者支气管舒张试验中用力肺活量(FVC),用力1秒呼气量(FEV1),50%肺活量时用力呼气容积(V50),25%肺活量时用力呼气容积(V25)的变化。结果应用支气管舒张剂后FVC、FEV1、V50、V25(%预计值)和绝对值均明显增加。以FEV1≥12%为标准,支气管舒张试验阳性率为67%。基础FEV1(%预计值)与舒张试验改变率(%)之间存在显著负相关。结论以FEV1作为支气管舒张试验的主要评价指标,必要时联合应用多项指标,结合临床资料加以综合评价。

Objective To evaluate the responses of forced vital capacity （FVC）, forced expiratory volume in one second（ FEV1 ） , forced expiratory volume of 50% FVC（V50） , and forced expiratory volume of 25% FVC（V25） to bronchodilator in patients with asthma. Methods FVCFEV1, V50, and V25were measured in 30 patients with asthma before and after 200txg salbutamol. Results Significant bronchodilating effects were detected after salbutamol assessed by FVC, FEVIV50, and V25. Significant bronchodilator reversibility was evident in 67% patients by ATS/ERS 200Criteria. Baseline lung functions （ FVC, FEV1 ） were significantly and negatively correlated bronchodilator reversibility. Conclusions FEVI should be used as the primary variable in assess in bronehodilator reversibility. Other variables and clinic information are also important for evaluation in the results of bronchodilator.